Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedPAC To Address Future Of “Pass-Through” Payments In March Report

This article was originally published in The Gray Sheet

Executive Summary

The Medicare Payment Advisory Commission will consider long-term strategies for the reimbursement of medical technology in the hospital outpatient setting and make a recommendation in its March 2002 report to Congress

You may also be interested in...



OPPS 2003 Proposed Rule Contains Payment Cuts For 80% Of Devices – Scully

Ambulatory payment classification 0107 (insertion of cardioverter-defibrillator leads) faces a 51% payment rate reduction compared with its 2002 reimbursement level, according to the hospital outpatient prospective payment system (OPPS) proposed rule for 2003

OPPS 2003 Proposed Rule Contains Payment Cuts For 80% Of Devices – Scully

Ambulatory payment classification 0107 (insertion of cardioverter-defibrillator leads) faces a 51% payment rate reduction compared with its 2002 reimbursement level, according to the hospital outpatient prospective payment system (OPPS) proposed rule for 2003

Medicare OPPS Administrative Burden On CMS Is Of Concern To MedPAC

The Medicare Payment Advisory Commission's upcoming recommendation on the future of the hospital outpatient prospective payment system (OPPS) "pass-through" payments is likely to hinge on the panel's perception of the size of the administrative undertaking for the Center for Medicare & Medicaid Services in implementing the system

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015747

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel